1. Home
  2. MIST vs CGTX Comparison

MIST vs CGTX Comparison

Compare MIST & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIST
  • CGTX
  • Stock Information
  • Founded
  • MIST 2003
  • CGTX 2007
  • Country
  • MIST Canada
  • CGTX United States
  • Employees
  • MIST N/A
  • CGTX N/A
  • Industry
  • MIST Biotechnology: Pharmaceutical Preparations
  • CGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MIST Health Care
  • CGTX Health Care
  • Exchange
  • MIST Nasdaq
  • CGTX Nasdaq
  • Market Cap
  • MIST 81.5M
  • CGTX 79.3M
  • IPO Year
  • MIST N/A
  • CGTX 2021
  • Fundamental
  • Price
  • MIST $1.43
  • CGTX $0.55
  • Analyst Decision
  • MIST Strong Buy
  • CGTX Buy
  • Analyst Count
  • MIST 3
  • CGTX 6
  • Target Price
  • MIST $13.00
  • CGTX $8.00
  • AVG Volume (30 Days)
  • MIST 177.8K
  • CGTX 588.8K
  • Earning Date
  • MIST 11-11-2024
  • CGTX 11-08-2024
  • Dividend Yield
  • MIST N/A
  • CGTX N/A
  • EPS Growth
  • MIST N/A
  • CGTX N/A
  • EPS
  • MIST N/A
  • CGTX N/A
  • Revenue
  • MIST N/A
  • CGTX N/A
  • Revenue This Year
  • MIST N/A
  • CGTX N/A
  • Revenue Next Year
  • MIST N/A
  • CGTX N/A
  • P/E Ratio
  • MIST N/A
  • CGTX N/A
  • Revenue Growth
  • MIST N/A
  • CGTX N/A
  • 52 Week Low
  • MIST $1.12
  • CGTX $0.34
  • 52 Week High
  • MIST $3.52
  • CGTX $2.95
  • Technical
  • Relative Strength Index (RSI)
  • MIST 42.50
  • CGTX 54.28
  • Support Level
  • MIST $1.41
  • CGTX $0.50
  • Resistance Level
  • MIST $1.53
  • CGTX $0.64
  • Average True Range (ATR)
  • MIST 0.07
  • CGTX 0.07
  • MACD
  • MIST -0.01
  • CGTX 0.02
  • Stochastic Oscillator
  • MIST 26.96
  • CGTX 67.74

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: